Comparative Pharmacology
Head-to-head clinical analysis: APRESOLINE versus FENOLDOPAM MESYLATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: APRESOLINE versus FENOLDOPAM MESYLATE.
APRESOLINE vs FENOLDOPAM MESYLATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Direct-acting arteriolar vasodilator that relaxes vascular smooth muscle, leading to decreased peripheral resistance and blood pressure. The exact molecular mechanism is unclear but may involve interference with calcium movement or inhibition of inositol trisphosphate-induced calcium release.
Dopamine D1-like receptor agonist (D1 and D5) causing vasodilation in renal, mesenteric, coronary, and cerebral arteries; increases renal blood flow and natriuresis.
Initial: 10 mg oral 4 times daily for 2-4 days; increase to 25 mg 4 times daily for the first week. Maintenance: 50 mg 4 times daily; maximum 300 mg/day. IV: 20-40 mg IM or slow IV push, repeat as needed.
0.1 to 0.3 mcg/kg/min IV continuous infusion, titrated every 15-20 minutes by 0.05-0.1 mcg/kg/min; max dose 1.6 mcg/kg/min.
None Documented
None Documented
Terminal elimination half-life is 3-7 hours in patients with normal renal function; prolonged to 7-16 hours in renal impairment. Acetylator phenotype affects half-life: in slow acetylators, half-life may be 4-5 hours; in fast acetylators, 1-2 hours, but clinical effect (antihypertensive) lasts longer due to persistent binding to vascular tissue.
Terminal elimination half-life approximately 10 minutes (range 5–20 min) in healthy adults; clinically, continuous infusion is required to maintain therapeutic effect due to rapid clearance.
Primarily renal; 86-90% of an oral dose is excreted in urine as metabolites (N-acetylhydralazine, hydralazine pyruvic acid hydrazone) and unchanged drug (<10% unchanged); biliary/fecal excretion is minimal (<10%).
Renal (80% as metabolites, 10% as unchanged drug); fecal/biliary minor (10%)
Category C
Category C
Antihypertensive
Antihypertensive